Flaxseed Lignans As Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets
Total Page：16
File Type：pdf, Size：1020Kb
Review Flaxseed Lignans as Important Dietary Polyphenols for Cancer Prevention and Treatment: Chemistry, Pharmacokinetics, and Molecular Targets S. Franklyn De Silva * and Jane Alcorn * Drug Discovery & Development Research Group, College of Pharmacy and Nutrition, 104 Clinic Place, Health Sciences Building, University of Saskatchewan, Saskatoon, Saskatchewan (SK), S7N 2Z4, Canada * Correspondence: [email protected] (J.A.); [email protected] (S.F.d.S.); Tel.: +1-306-966-6365 (J.A.) Received: 22 March 2019; Accepted: 30 April 2019; Published: 5 May 2019 Abstract: Cancer causes considerable morbidity and mortality across the world. Socioeconomic, environmental, and lifestyle factors contribute to the increasing cancer prevalence, bespeaking a need for effective prevention and treatment strategies. Phytochemicals like plant polyphenols are generally considered to have anticancer, anti-inflammatory, antiviral, antimicrobial, and immunomodulatory effects, which explain their promotion for human health. The past several decades have contributed to a growing evidence base in the literature that demonstrate ability of polyphenols to modulate multiple targets of carcinogenesis linking models of cancer characteristics (i.e., hallmarks and nutraceutical-based targeting of cancer) via direct or indirect interaction or modulation of cellular and molecular targets. This evidence is particularly relevant for the lignans, an ubiquitous, important class of dietary polyphenols present in high levels in food sources such as flaxseed. Literature evidence on lignans suggests potential benefit in cancer prevention and treatment. This review summarizes the relevant chemical and pharmacokinetic properties of dietary polyphenols and specifically focuses on the biological targets of flaxseed lignans. The consolidation of the considerable body of data on the diverse targets of the lignans will aid continued research into their potential for use in combination with other cancer chemotherapies, utilizing flaxseed lignan-enriched natural products. Keywords: Flaxseed lignans; Dietary polyphenols; Phytochemicals; Cellular/molecular targets; Pharmacokinetics; Chemopreventive; Chemotherapeutic; Hallmarks of cancer; Quality of life 1. Introduction The exploration of alternative strategies for cancer prevention and treatment has become necessary owing to the high costs of current chemotherapies, prolonged time in regulatory authorization processes for new cancer treatments, and the considerable expenditure associated with taking a medicinal agent from bench to bed-side. Repositioning of noncancer therapeutics, such as plant polyphenols, to treat cancer offers an alternate strategy to address these challenges. Such therapeutic interventions are usually associated with lower costs and manageable toxicity with concomitant improvement in quality of life. Plant polyphenols have a long history of proposed benefits in the prevention and treatment of a chronic disease like cancer [1–4]. Although the evidence for health benefits of plant polyphenols is available throughout the literature, the flaxseed polyphenols have gained increasing attention. Flaxseed contains numerous nutrient and non-nutrient chemical constituents, like α-linolenic acid, fiber, and lignans, which can support our well-being [5–20]. More recently, polyphenols of flaxseed—the lignans—have sparked increased interest mostly attributing to their antioxidative, anti-inflammatory, anti-atherosclerogenic, and Pharmaceuticals 2019, 12, 68; doi:10.3390/ph12020068 www.mdpi.com/journal/pharmaceuticals Pharmaceuticals 2019, 12, 68 2 of 67 antiestrogenic potential, thus suggesting ability to reduce risk and protect against cancer [16,21–38]. Such attributes have compelled expansion of investigations into lignan mechanisms of action. Plant lignans [39], different from lignins (racemic polymers that are components of the plant cell wall [39,40]), are non-nutrient, noncaloric, bioactive phenolic plant compounds [39]. Diverse lignanoid constituents from plant-based food resources [41], like secoisolariciresinol diglucoside (SDG) [42], lariciresinol [41], isolariciresinol [43], 7-hydroxymatairesinol [44], matairesinol (MAT) [45], pinoresinol, arctigenin, syringaresinol [46], and asarinin [47], can be precursors of enterolignans—the mammalian-derived lignans—following oral consumption of plant lignans [39]. The primary intent of this review is to consolidate the evidence of lignan pharmacokinetics and modulation of cellular processes and cell signaling pathways within the cancer phenotype so as to provide opportunity to direct future investigations into the role and benefit of the dietary polyphenols, specifically flaxseed lignans, in the prevention and treatment of cancer (i.e., complementary and integrative medicine [48]). 2. Growing Use of Naturally Derived Products Unsatisfactory results of Western medicine have given complementary and alternative treatment options more attention [49]. Many patients rely on phytochemicals and herbal medicines (collectively referred to as natural health products (NHPs) for the purpose of this review) for primary health care, especially in the developing world [50]. In developed countries, NHPs are used to promote healthier living [50]. Although several NHPs have promising effects with wide utilization, some remain untested with clinical use unmonitored and undocumented [50], while some NHPs have safety concerns [51]. Existence of a regulatory framework for NHPs provides greater reassurance to consumers; however, regulations and product quality specification vary among countries [49]. As an example, the Dietary Supplement Health and Education Act (DSHEA) of 1994 provided the U.S. FDA the authority to implement Good Manufacturing Practices (GMP) for dietary supplements and ensure safety of such products, and the framework of the Federal Food, Drug, and Cosmetic Act, which led to the DSHEA, provides the necessary framework needed by the Food and Drug Administration (FDA) to regulate dietary supplements [52]. Additionally, in Canada, NHPs approved by Health Canada (e.g., herbal remedies [53]) are regulated under the Natural and Non-Prescription Health Products Directorate [54]. This allows for large production and lower prices (due to competition) by companies, even though NHPs are regulated somewhat similar to pharmaceutical drugs under the Natural Health Products Regulation (NHPR). These regulations protect Canadians by ensuring that the products obtained meet their health needs [55,56]. Regardless of the preclinical evidence of NHPs, translational capabilities into the clinic can be hampered by similar factors encountered by drugs in development such as the dose size and dosage forms and the variability in outcomes caused by gender, ethnicity, and comorbidities [55]. 3. Cancer, the Unmet Medical Need Cancer was identified as an important human disease thousands of years ago [57]. In the subsequent thousands of years cancer patients faced little hope for cure and survival, a situation unchanged for some cancers and clearly an unmet medical need for these patients. Globally, cancer contributes to considerable mortality with estimates projected to increase from 14 million new cases per year in 2012 [2] to an estimated 19.3 million cases yearly by 2025 [58,59]. Colorectal, liver, breast, gastric, prostate, cervical, and lung cancers remain the principal causes of cancer deaths [2], and the majority of cancer related mortality occurs in low- and middle-income countries [60,61]. Surgery, radiotherapy, and systemic therapy, which include general chemotherapy, hormonal therapy, immunotherapy, and targeted therapies, are the current treatments of cancer [58]. In too many patients these treatments fail, and cancer remains a major challenge to clinical interventions. A need exists to discover more effective ways of targeting cancer and new avenues of disease management might offer some potential. Today’s improved understanding of the characteristics of cancer offer renewed hope for treating cancer. The pioneering work of Weinberg and colleagues to categorize the cancer Pharmaceuticals 2019, 12, 68 3 of 67 characteristics into distinct tumor properties, the so-called “Hallmarks of Cancer”, provide a framework around which to rally the considerable scientific and technological advances to identify more effective treatments for different cancer phenotypes [62,63]. Among the different cancer characteristics, mutations enable malignant cells both continuity and survival. These driver mutations stem from various mechanisms including carcinogen exposure [57]. Carcinogenesis is a complex multifactorial and multistep process separated into three closely related stages: initiation, promotion, and progression [64–67] (Figure 1). The first stage, initiation, follows usually from carcinogen (or its metabolite) exposure and is traditionally considered an irreversible step with one or more genetic alterations resulting from DNA mutations, transitions, transversions, or deletions [65,68]. Promotion is the second stage and is considered a reversible stage where the proliferation of neoplastic cells takes prominence [65]. This stage does not involve DNA structural changes but rather changes in genome expressions brought out by promoter–receptor interactions [68]. Tumor progression is the last stage where neoplastic transformation occurs followed by tumor growth, invasion, and metastasis [65]. Stages of carcinogenesis are governed by proto-oncogenes, cellular oncogenes, and tumor suppressor genes. These